CBER Director Peter Marks and former FDA Deputy Commissioner Janet Woodcock (Greg Nash/Pool via AP Images; Michael Brochstein/Sipa USA/Sipa via AP Images)

May 22, 2024 12:43 PM EDT

FDA+

FDA's Marks, Woodcock talk regulatory flexibility for new rare disease drugs

Lia DeGroot

The FDA’s top biologics chief and a former deputy commissioner on Tuesday discussed the need for regulatory flexibility for rare disease therapies and underscored the …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

FDA's Marks, Woodcock talk regulatory flexibility for new rare disease drugs

Lia DeGroot

Sign up to read this article for free.

Associate Director, Market Insights and Analytics

Celldex Therapeutics

Hampton, NJ, USA

Autoimmune CAR-T data dump: Kyverna, Cabaletta shares fall after unveiling early-stage results

Rare pediatric disease vouchers face uncertain future after September

Gilead cancer drug magrolimab showed worrying trends around death

Stephen Squinto talks writing checks and next-gen obesity drugs as JP Morgan closes first $500M+ biotech fund

AI drug discovery startup goes public in Hong Kong, nabbing $115M to build on pharma partnerships

De-risking the patient journey in cell therapies: Six key considerations

FDA's Marks, Wood­cock talk reg­u­la­to­ry flex­i­bil­i­ty for new rare dis­ease drugs

Sign up to read this article for free.

Celldex Therapeutics

Hampton, NJ, USA

FDA's Marks, Woodcock talk regulatory flexibility for new rare disease drugs